Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....

#SymptomScience pilot study showing feasibility of low-intensity vibration to reduce #CIPN and improve physical function in cancer survivors @advocatecollab.bsky.social @ascocancer.bsky.social @cancercaremascc.bsky.social @pallonccop.bsky.social @ryannipp.bsky.social ascopubs.org/doi/10.1200/...

Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update ASCO–Society for Integrative Oncology (SIO) Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline develo...

Here is a great @ascocancer.bsky.social JCO #ASCOGuidelines resource ascopubs.org/doi/10.1200/... #SymptomScience

Thankful @nejm.org #CancerCachexia ponsegromab study highlighted as NEJM Notable Articles of 2024 #SymptomScience www.nejm.org/doi/full/10.... @ascocancer.bsky.social @cancercachexia.bsky.social @pallonccop.bsky.social @cancercaremascc.bsky.social @ohsuknight.bsky.social @drr-dunne.bsky.social

Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer This randomized clinical trial investigates whether a single oral dose of cannabidiol improves scan-related anxiety in women with advanced breast cancer.

@jama.com #scanxiety RCT of CBD v placebo in women with #breastcancer (n=50) led by @ascocancer.bsky.social Cannabis #ASCOGuidelines Co-Chair, Dr. Ilana Braun. No difference primary end point (VAMS afraid subscale). More work to be done #PallOnc #SymptomScience jamanetwork.com/journals/jam...

@sarahlowry.bsky.social Welcome my friend. Glad to see you here. Where are all our incredible APP colleagues? #PallOnc #OncSky #PallSky #SymptomScience